OptiNose (NASDAQ:OPTN) Price Target Lowered to $17.00 at Lake Street Capital

OptiNose (NASDAQ:OPTN) had its price objective cut by Lake Street Capital from $45.00 to $17.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. HC Wainwright upped their price objective on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Piper Sandler reduced their price objective on OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th.

OptiNose Stock Performance

Shares of NASDAQ:OPTN opened at $6.03 on Thursday. OptiNose has a one year low of $4.82 and a one year high of $31.50. The business’s fifty day moving average price is $6.89 and its two-hundred day moving average price is $11.20. The stock has a market cap of $60.66 million, a PE ratio of -1.44 and a beta of -0.15.

Institutional Trading of OptiNose

A number of hedge funds have recently made changes to their positions in OPTN. FMR LLC boosted its position in OptiNose by 3.2% in the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after buying an additional 518,610 shares during the last quarter. Great Point Partners LLC lifted its stake in OptiNose by 56.2% during the second quarter. Great Point Partners LLC now owns 13,727,097 shares of the company’s stock worth $14,276,000 after purchasing an additional 4,940,779 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in shares of OptiNose by 442.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 13,418,740 shares of the company’s stock valued at $14,425,000 after buying an additional 10,944,444 shares during the period. Rosalind Advisors Inc. boosted its stake in OptiNose by 9.8% in the third quarter. Rosalind Advisors Inc. now owns 8,287,503 shares of the company’s stock valued at $5,553,000 after acquiring an additional 740,355 shares during the period. Finally, Stonepine Capital Management LLC boosted its position in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock valued at $3,811,000 after purchasing an additional 3,338,580 shares during the period. Hedge funds and other institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.